Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

NCT03333694 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
40
Enrollment
INDUSTRY
Sponsor class

Stopped The study fully enrolled and completed after last patient completed the study

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals